Idt Australia Limited · ASX:IDT
Idt Australia — FY2026 Earnings Presentation
12 slides from Idt Australia's earnings presentation, Aug 20, 2026
Slide 1: Full Year Results FY26
For personal use only Full Year Results FY26 August 2026 Advanced Manufacturing for Breakthrough Medicines
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, background information only which is current at the date o
Slide 3: FY26 Results at a Glance: Turning Point
FY26 RESULTS AT A GLANCE Turning Point FY26 EBITDA REVENUE, 3 VERTICALS TOTAL REVENUE (inc disb) AVAILABLE FUNDS $16.8M $20.4M $9.7M For personal use only –$0.9M ▲ 85% YoY FY25: –$6.3M ▲ 16.5% YoY FY25: $14.4M ▲ vs FY25 FY25: $19.2M to Fund Growth Three Verticals The Turnaround Strategic Reset Objec
Slide 4: Verticals — Business Performance
Verticals — Business Performance Core growth platforms For personal use only Active Pharmaceutical Solid Oral Manufacturing Sterile Manufacturing Ingredient (API) Revenue up 29% to $5.4M Revenue up 52% to $5.5M Revenue down 11% to $5.9M • Small-molecule, complex high-potency • Capitalising on radiop
Slide 5: Operational Momentum: Strong Near and Medium-Term Outlook
Operational Momentum Strong Near and Medium-Term Outlook NEAR- & MEDIUM-TERM DRIVERS For personal use only 1 2 3 4 Repeat & follow-on work Expand capabilities Deepen IDT's competitiveness Increase market visibility with existing strategic clients in to position IDT as one of the few to back new cust
Slide 6: Global Market Overview
Global Market Overview Growth Across all Three Verticals For personal use only IDT is a specialist, agile CDMO focused on complex Small-Molecule API, and Sterile & Non-Sterile TAM - US$130B+ manufacturing — delivering the agility and responsiveness required by emerging biotech and pharmaceutical com
Slide 7: Pathway to $50M Revenue
Pathway to $50M Revenue FY29 Revenue Target Strategic positioning For personal use only 01 Specialist in complex small-molecule API and sterile & non-sterile manufacturing Positioning — an agile solution for emerging biotech and pharma. Existing customer expansion Customer Expansion 02 Maximise valu
Slide 8: High-Tech Capability Expansion
High-Tech Capability Expansion $7M Business Investment For personal use only New Sterile Manufacturing Line Isolator Technology — the global gold standard for Grade A aseptic fill-finish • Enables commercial-scale fill-finish • Fully vertically integrated finished-dose service • Serves ADCs, Biologi
Slide 9: Outlook and Highlights
Outlook and Highlights The confident path forward For personal use only Profit Recovery FY27 Outlook • Improved operating leverage — EBITDA improvement 85% on • Double digit revenue growth 16.5% revenue growth in FY26 • Positive EBITDA forecast for the year • FY26 cost savings - ~$2.5m • Strong pipe
Slide 10: Board of Directors
Board of Directors Experienced board and leadership team Mark Simari For personal use only An experienced and accomplished professional in the health industry with over 17 years' board experience across a diverse range of organisations. Former managing director and co-founder of Paragon Care (2008–
Slide 11: Investor & Media Enquiries
For personal use only Investor & Media Enquiries Brendon Lau brendon@vantagepointpartners.com.au +61 409 341 613 Advanced Manufacturing for Breakthrough Medicines
Slide 12: Appendix: References & Definitions
Appendix REFERENCES & DEFINITIONS For personal use only REFERENCES DEFINITIONS 1 Mordor Intelligence — Active Pharmaceutical Ingredients (API) market Total Addressable Market mordorintelligence.com/industry-reports/global-active-pharmaceutical-ingredients-api-market TAM Total market demand — the max